Pharsight

Drugs that contain Eslicarbazepine Acetate

1. Aptiom patents expiration

APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5753646 SUMITOMO PHARMA AM Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Jun, 2021

(2 years ago)

US9206135 SUMITOMO PHARMA AM Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11364247 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 15 days from now)

US10675287 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 15 days from now)

US10695354 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 15 days from now)

US10702536 SUMITOMO PHARMA AM Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 15 days from now)

US9643929 SUMITOMO PHARMA AM Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(2 years from now)

US9763954 SUMITOMO PHARMA AM Therapeutical uses of eslicarbazepine
Sep, 2028

(4 years from now)

US9566244 SUMITOMO PHARMA AM Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(4 years from now)

US10912781 SUMITOMO PHARMA AM Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(4 years from now)

US8372431 SUMITOMO PHARMA AM Pharmaceutical composition comprising licarbazepine acetate
Apr, 2030

(5 years from now)

US9750747 SUMITOMO PHARMA AM Treatments involving eslicarbazepine acetate or eslicarbazepine
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have bee...

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents